JB
GEVA

Julian Baker’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Julian Baker’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-11,660,432
Closed -$1.14B – 135
2015
Q1 		$1.14B Buy
11,660,432
+1,000,000
+9% +$106M 9.46% 3
2014
Q4 		$989M Hold
10,660,432
– – 10.1% 3
2014
Q3 		$733M Hold
10,660,432
– – 9.23% 4
2014
Q2 		$1.12B Buy
10,660,432
+12,250
+0.1% +$1.04M 13.68% 1
2014
Q1 		$883M Buy
10,648,182
+375,000
+4% +$34.7M 11.23% 2
2013
Q4 		$665M Hold
10,273,182
– – 9.37% 4
2013
Q3 		$651M Buy
10,273,182
+1,050,000
+11% +$51.7M 9.26% 4
2013
Q2 		$387M Buy
+9,223,182
New +$420M 7.66% 5

Julian Baker's GEVA Position: Q2 2015 in Review

Julian Baker sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 11,660,432 shares — an estimated $1.14B sold.

Julian Baker first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $1.14B in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Julian Baker reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Julian Baker sold 11,660,432 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $1.14B.
  • Julian Baker first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Julian Baker's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $1.14B in Q1 2015.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Baker Bros. Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.